Jens H Westhoff1, Felix S Seibert2, Sina Waldherr3, Frederic Bauer2, Burkhard Tönshoff4, Alexander Fichtner4, Timm H Westhoff2. 1. Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. jens.westhoff@med.uni-heidelberg.de. 2. Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Bochum, Germany. 3. Department of Neonatology, University Children's Hospital, Heidelberg, Germany. 4. Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Abstract
Early identification of patients with acute kidney injury (AKI) being at high risk for adverse outcome can influence medical treatment. This study compares urinary calprotectin, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) for their performance in predicting mortality and need for renal replacement therapy (RRT) in pediatric AKI patients. Urinary biomarker concentrations were assessed prospectively in 141 subjects aged 0-18 years including 55 patients with established AKI according to pediatric Risk, Injury, Failure, Loss, and End-stage kidney disease (pRIFLE) criteria, 27 patients without AKI, and 59 healthy children. Within the AKI group, receiver operating characteristic (ROC) curve analysis revealed moderate to poor performance of calprotectin and KIM-1 in the prediction of 30-day mortality (calprotectin area under the curve (AUC) 0.55; KIM-1 AUC 0.55) and 3-month mortality (calprotectin AUC 0.61; KIM-1 AUC 0.60) and fair performance in the prediction of RRT requirement (calprotectin AUC 0.72; KIM-1 AUC 0.71). Urinary NGAL showed good performance in predicting 30-day (AUC 0.79) and 3-month (AUC 0.81) mortality and moderate performance in predicting RRT (AUC 0.61). CONCLUSIONS: Whereas urinary calprotectin and KIM-1 can be useful for the prediction of RRT, urinary NGAL has a good diagnostic performance in predicting mortality in pediatric patients with AKI of heterogeneous etiology. What is known: • There is increasing evidence that urinary biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are valuable for the prediction of adverse outcome in adult acute kidney injury (AKI), whereas data on pediatric AKI is scarce. What is new: • Urinary calprotectin and KIM-1 do not predict mortality in our heterogeneous pediatric AKI cohort, but they show moderate performance in the prediction of dialysis. • Urinary NGAL is a good predictor of mortality performing better than pRIFLE stage, eGFR, or creatinine, but it shows moderate performance in the prediction of dialysis.
Early identification of patients with acute kidney injury (AKI) being at high risk for adverse outcome can influence medical treatment. This study compares urinary calprotectin, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) for their performance in predicting mortality and need for renal replacement therapy (RRT) in pediatric AKI patients. Urinary biomarker concentrations were assessed prospectively in 141 subjects aged 0-18 years including 55 patients with established AKI according to pediatric Risk, Injury, Failure, Loss, and End-stage kidney disease (pRIFLE) criteria, 27 patients without AKI, and 59 healthy children. Within the AKI group, receiver operating characteristic (ROC) curve analysis revealed moderate to poor performance of calprotectin and KIM-1 in the prediction of 30-day mortality (calprotectin area under the curve (AUC) 0.55; KIM-1 AUC 0.55) and 3-month mortality (calprotectin AUC 0.61; KIM-1 AUC 0.60) and fair performance in the prediction of RRT requirement (calprotectin AUC 0.72; KIM-1 AUC 0.71). Urinary NGAL showed good performance in predicting 30-day (AUC 0.79) and 3-month (AUC 0.81) mortality and moderate performance in predicting RRT (AUC 0.61). CONCLUSIONS: Whereas urinary calprotectin and KIM-1 can be useful for the prediction of RRT, urinary NGAL has a good diagnostic performance in predicting mortality in pediatric patients with AKI of heterogeneous etiology. What is known: • There is increasing evidence that urinary biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are valuable for the prediction of adverse outcome in adult acute kidney injury (AKI), whereas data on pediatric AKI is scarce. What is new: • Urinary calprotectin and KIM-1 do not predict mortality in our heterogeneous pediatric AKI cohort, but they show moderate performance in the prediction of dialysis. • Urinary NGAL is a good predictor of mortality performing better than pRIFLE stage, eGFR, or creatinine, but it shows moderate performance in the prediction of dialysis.
Authors: Thomas L Nickolas; Kai M Schmidt-Ott; Pietro Canetta; Catherine Forster; Eugenia Singer; Meghan Sise; Antje Elger; Omar Maarouf; David Antonio Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J Saggi; Barry Hahn; Ralph Kettritz; Friedrich C Luft; Jonathan Barasch Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Dinna N Cruz; Sean M Bagshaw; Alan Maisel; Andrew Lewington; Ravi Thadhani; Rajasekara Chakravarthi; Patrick T Murray; Ravindra L Mehta; Lakhmir S Chawla Journal: Contrib Nephrol Date: 2013-05-13 Impact factor: 1.580
Authors: A Akcan-Arikan; M Zappitelli; L L Loftis; K K Washburn; L S Jefferson; S L Goldstein Journal: Kidney Int Date: 2007-03-28 Impact factor: 10.612
Authors: Patrick T Murray; Ravindra L Mehta; Andrew Shaw; Claudio Ronco; Zoltan Endre; John A Kellum; Lakhmir S Chawla; Dinna Cruz; Can Ince; Mark D Okusa Journal: Kidney Int Date: 2013-10-09 Impact factor: 10.612
Authors: Paul Luchian Aldea; Andreea Liana Rachisan; Bogdan Ioan Stanciu; Andrei Picos; Alina Monica Picos; Dan Ioan Delean; Ramona Stroescu; Magdalena Iuliana Starcea; Cristina Maria Borzan; Florin Ioan Elec Journal: Front Pediatr Date: 2022-06-03 Impact factor: 3.569
Authors: Eryk Latoch; Katarzyna Konończuk; Katarzyna Taranta-Janusz; Katarzyna Muszyńska-Rosłan; Edyta Szymczak; Anna Wasilewska; Maryna Krawczuk-Rybak Journal: Cancer Chemother Pharmacol Date: 2020-10-14 Impact factor: 3.333